2 May 2017 - Cell therapy company jCyte announced that the U.S. FDA has granted regenerative medicine advanced therapy designation for the company’s developmental retinitis pigmentosa treatment, jCell. 

Regenerative medicine advanced therapy seeks to accelerate approval for regenerative therapies that demonstrate the potential to address an unmet medical need.

jCell contains human retinal progenitor cells, which release neurotrophic factors that may rescue diseased retinal cells, as well as possibly integrating into the retina as new cells. This investigational therapy is delivered with a simple intra-vitreal injection, performed under topical anaesthesia, in a matter of minutes.

Read JCyte press release